SCHEMBL770487

SCHEMBL770487

O=C(CN1C(=O)c2cc(Cl)c(Cl)cc2C1=O)N1CCCC2CCCC=C21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 1/20 0.33
ALDH1A1 P00352 6/20 0.32
KDM4E B2RXH2 4/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 4/20 0.32
LMNA P02545 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
PRCP P42785 2/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
GAA P10253 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
AGTR1 P30556 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769925 0.89 ALDH1A1 (0.40) HSD17B10KMT2AALDH1A1MAPTHPGD
SCHEMBL771566 0.87 ALDH1A1 (0.42) HSD17B10MEN1KMT2AALDH1A1MAPT
SCHEMBL771238 0.86 ALDH1A1 (0.41) ALDH1A1KDM4EMAPTHPGDLMNA
SCHEMBL770504 0.86 HSD17B10 (0.52) HSD17B10MEN1KMT2APOLBALDH1A1
SCHEMBL770807 0.84 HSD17B10 (0.39) HSD17B10MEN1KMT2APOLBALDH1A1
SCHEMBL770404 0.78 HSD17B10 (0.40) HSD17B10MEN1KMT2APOLBALDH1A1
SCHEMBL771129 0.78 KMT2A (0.41) HSD17B10MEN1KMT2APOLBALDH1A1
SCHEMBL771557 0.77 HSD17B10 (0.38) HSD17B10MEN1KMT2APOLBALDH1A1
SCHEMBL770257 0.76 ALDH1A1 (0.37) ALDH1A1LMNA
SCHEMBL771484 0.75 LMNA (0.30) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HSD17B10 19/4885MEN1 827/4885KMT2A 3868/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HSD17B10 19/4885MEN1 823/4885KMT2A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.